Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544063 | 0.92 | PTGDR2 (0.41) | CASP3SENP8SENP7SENP6MEN1 | |
| SCHEMBL15544581 | 0.88 | GRIN2B (0.41) | MEN1KMT2APTGDR2POLBALDH1A1 | |
| SCHEMBL15544959 | 0.87 | PTGDR2 (0.43) | MEN1PKMKMT2APTGDR2ALDH1A1 | |
| SCHEMBL15545181 | 0.85 | PTGDR2 (0.43) | PTGDR2ALDH1A1L3MBTL1 | |
| SCHEMBL15543943 | 0.84 | P2RX4 (0.40) | MEN1KMT2APTGDR2ALDH1A1L3MBTL1 | |
| SCHEMBL15546005 | 0.84 | PTGDR2 (0.41) | PTGDR2F13A1TGM2TGM1GRIN2B | |
| SCHEMBL15545593 | 0.83 | PTGDR2 (0.45) | PTGDR2 | |
| SCHEMBL16765891 | 0.83 | PTGDR2 (0.40) | PTGDR2ALDH1A1MAPTGRIN2B | |
| SCHEMBL15545036 | 0.82 | PTGDR2 (0.39) | MEN1KMT2APTGDR2POLBALDH1A1 | |
| SCHEMBL15544699 | 0.81 | PTGDR2 (0.43) | PKMPTGDR2ALDH1A1ENPP2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169270-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-27 | — | — | US | disclosed |
| EP-2885307-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-20150158883-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICAL LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| WO-2014006585-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158883-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | CASP3 3663/4885SENP8 4659/4885SENP7 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.